Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment
Recruiting
Phase 2
Interventional Study
Cognition
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 60 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Distribuidora Biolife SA de CV · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of this randomized, triple-blind, placebo-controlled clinical trial is to compare NANO-PSO therapy against placebo in improving cognitive abilities in older adults with mild to moderate non-vascular cognitive impairment over six months of treatment. The primary questions it aims to answer are:
• Does NANO-PSO therapy improve cognitive abilities in older adults with mild to moderate …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients attended at the Hospital Español.
* Patients of any gender who are 60 years or older.
* Patients presenting with mild to moderate cognitive impairment.
* Meet the diagnostic criteria for \"probable dementia\" of the National Institute on Aging and the Alzheime…
Contacts
Alejandro Padilla Isassi, Geriatrician and researcher
+525589510727
alejandropadillaisassi@gmail.com
CONTACT